Amgen (AMGN) yields 2.6% with a $10.08 annualized payout, topping Merck (MRK) at 2.29%, and has raised its dividend 6% annually versus Merck’s smaller step-ups.
Amgen’s 17 billion-dollar products and $3.5B quarterly free cash flow dwarf Merck’s reliance on a single Keytruda franchise facing peak penetration.
Merck absorbed a $5.7B acquisition charge that pushed Q2 earnings to a loss, while Amgen raised 2026 EPS guidance to as high as $23.50.
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn’t make the cut. Enter your email to see the names that beat MRK. The report is free. Enter your email and see if any of your stocks made the cut.
For a retirement portfolio that leans on pharma dividends, the choice between Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK) comes down to one question: which check is more likely to keep getting bigger through the next wave of patent expirations? Both companies deliver quarterly income today. Only one has the coverage, the growth cadence, and the portfolio breadth to keep raising through the cliff.
poba / Getty Images
Yield and Raw Income Today
Amgen pays a quarterly dividend of $2.52 per share, an annualized forward payout of $10.08. At $385.28, that lands at a yield of roughly 2.6%. Merck pays $0.85 quarterly, or $3.40 annualized, and at $146.65 yields 2.29%.
On starting yield, Amgen wins. It is not a wide gap, but for a retiree sizing positions to hit an income target, the difference compounds. An investor putting $100,000 to work today gets meaningfully more current cash from AMGN, and the gap holds even after Merck’s 85.17% one-year rally compressed its yield. Winner: Amgen.
Both boards raise annually, and both raised again this year. The verified quarterly progression tells the story.
Free Report, Just Released
Why Didn’t MRK Make The Top 10 List?
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
And MRK didn’t make the cut!
The report is free, and you can see why we think each stock is a top investment today.
Amgen: $2.13 (2023) to $2.25 (2024) to $2.38 (2025) to $2.52 (2026). Management characterized the latest hike as a 6% increase, matching the pace of the prior year’s raise.
Merck: $0.73 (2023) to $0.77 (2024) to $0.81 (2025) to $0.85 (2026). The 2026 hike from $0.81 to $0.85 is a smaller step in dollar terms and in percentage terms than Amgen’s.
Amgen has been pushing 6% raises consistently while Merck’s step-ups have been closer to the mid-single-digit range with a smaller relative bump this cycle. For an income holder who needs the payout to outrun inflation, Amgen’s steeper trajectory matters more than Merck’s slightly larger share count leverage. Winner: Amgen.
This is where the matchup is decided. Merck’s Keytruda franchise generated $8.4 billion in Q2 2026 sales, and the CFO warned that “total U.S. Keytruda year-over-year growth will moderate as we increasingly reach peak penetration.” The company’s answer is a $70 billion commercial opportunity across more than 20 new products, with the CEO framing loss of exclusivity as “more of a hill than a cliff.” That is a bet on pipeline execution, and the Q2 quarter absorbed a $5.7 billion charge tied to the Terns acquisition, pushing GAAP earnings to a $0.13 per share loss.
Amgen’s income base is broader by design. In Q2 2026 the company reported $3.5 billion in free cash flow, 22 products with double-digit growth, and 17 products annualizing above $1 billion. Six growth drivers, Repatha, Evenity, Tezspire, rare disease, innovative oncology, and biosimilars, grew 26% collectively and now represent nearly 70% of product sales. Biosimilar erosion is already visible in Prolia and Xgeva, down 33% together, and the dividend kept rising through it.
The balance sheet is the caveat. Amgen carries $57.3 billion in debt at roughly 3.2x EBITDA, higher leverage than Merck’s investment-grade profile. But quarterly free cash flow of $3.5 billion comfortably covers a payout that runs near $1.4 billion per quarter, and management’s raised 2026 EPS guidance to $22.30 to $23.50 keeps coverage climbing. Winner: Amgen.
AMGN Analyst Ratings — 24/7 Wall St.
MRK Analyst Ratings — 24/7 Wall St.
Verdict
For the retirement-focused income investor, Amgen is the pick. It pays more today, raises faster, and rests on 17 billion-dollar products rather than one $8 billion franchise staring at loss of exclusivity. Merck is a fine capital-appreciation story if the pipeline delivers on the CEO’s “shallow dip” promise, and it belongs in a growth-tilted portfolio betting on the Keytruda successors. But dividend durability is a diversification question, and Amgen already has the diversification Merck is still trying to build.
If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And MRK wasn’t one of them.
They combed the entire market. It’s not 10 ideas, not 10 stocks everyone is talking about, it’s what their research points to as the 10 best stocks to buy right now, and it’s free. Read more here and see which stocks made the list –>>
Contact editorial@247wallst.com for any questions or corrections.
